

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)

Meeting – June 11, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

2. Introduction of New Board Member

Items to be presented by Dr. Muchmore, Chairman:

3. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

4. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. May 14, 2014 DUR Minutes – Vote
- B. May 14, 2014 DUR Recommendation Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Update of Medication Coverage Authorization Unit/ FDA Safety Alerts – See Appendix B

- A. Medication Coverage Activity for May 2014
- B. Pharmacy Help Desk Activity for May 2014
- C. FDA Safety Alerts

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. Utilization Breakdown of Hydrocodone Containing Medications – See Appendix C

- A. Utilization of Hydrocodone
- B. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Sovaldi™ (Sofosbuvir), Olysio™ (Simeprevir), Victrelis® (Boceprevir), and Incivek® (Telaprevir) – See Appendix D

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Trokendi XR™ (Topiramate ER), Aptiom® (Eslicarbazepine Acetate), Qudexy™ XR (Topiramate ER), and Generic Divalproex ER – See Appendix E

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 9. Annual Review of Triptan Anti-Migraine Medications and 30-Day Notice to Prior Authorize Zecuity® (Sumatriptan Iontophoretic Transdermal System) – See Appendix F**
 - A. Current Authorization Criteria
 - B. Utilization of Triptan Anti-Migraine Medications
 - C. Prior Authorization
 - D. Market News and Updates
 - E. Summary
 - F. COP Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

- 10. Annual Review of Anti-Ulcer Medications and 30-Day Notice to Prior Authorize Esomeprazole Strontium and Aciphex® Sprinkle™ (Rabeprazole) – See Appendix G**
 - A. Current Authorization Criteria
 - B. Utilization of Anti-Ulcer Medications
 - C. Prior Authorization
 - D. Market News and Updates
 - E. Summary
 - F. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 11. Annual review of Antihyperlipidemics and 30-Day Notice to Prior Authorize Liptruzet™ (Ezetimibe/Atorvastatin) and Omtryg™ (Omega-3-Acid Ethyl Esters A) – See Appendix H**
 - A. Current Authorization Criteria
 - B. Utilization of Antihyperlipidemic Medications
 - C. Prior Authorization
 - D. Market News and Updates
 - E. Summary
 - F. Discussion
 - G. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

- 12. FDA and DEA Updates – See Appendix I**

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

- 13. Future Business**
 - A. Annual Reviews
 - B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

- 14. Adjournment**